Sangamo Therapeutics recently reported detailed data from its completed registrational Phase 1/2 STAAR study of isaralgagene civaparvovec (ST-920) for Fabry disease, alongside confirmation that the ...
NEW YORK/LONDON, Feb 3 (Reuters) - A significant selloff among U.S. and European data analytics, professional services and software companies deepened on Tuesday, with some investors pointing to a ...
Katherine Haan, MBA, is a Senior Staff Writer for Forbes Advisor and a former financial advisor turned international bestselling author and business coach. For more than a decade, she’s helped small ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results